How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comStudy on the Use of 68Ga-EVG321 for Diagnosing Small Cell Lung Cancer in Patients
Description:
The trial aims to compare the imaging results with traditional methods of diagnosing SCLC to see if 68Ga-EVG321 can provide more accurate information about the presence of cancer. By doing so, the study hopes to improve the understanding of how this diagnostic tool can be used in the future to help detect and manage Small Cell Lung Cancer more effectively.
Sponsor:
Evergreen Theragnostics, Inc.
Government Study Link:
EuropeNotInCTCdotGov - Click here to see study onClinicalTrials.gov
68Ga-EVG321
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- Cholecystokinin-2 (CCK2R)
Share your feedback
Help us improve your experience